US4960765A
(en)
*
|
1980-03-20 |
1990-10-02 |
Farmaceutisk Laboratorium Ferring A/S |
Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
|
JPS57500432A
(de)
*
|
1980-03-20 |
1982-03-11 |
|
|
SE457505B
(sv)
*
|
1984-01-10 |
1989-01-09 |
Lejus Medical Ab |
Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
|
IL77186A0
(en)
*
|
1985-11-29 |
1986-04-29 |
Touitou Elka |
Pharmaceutical insulin composition
|
DE3775880D1
(de)
*
|
1986-09-18 |
1992-02-20 |
London School Of Pharmacy Innovations Ltd., London, Gb |
|
GB8707421D0
(en)
*
|
1987-03-27 |
1987-04-29 |
Wellcome Found |
Pharmaceutical formulations
|
JPH01299226A
(ja)
*
|
1988-05-27 |
1989-12-04 |
Seikagaku Kogyo Co Ltd |
サラゾスルファピリジン腸溶顆粒
|
PT93637A
(pt)
*
|
1989-04-20 |
1990-11-20 |
Procter & Gamble |
Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
|
US5032405A
(en)
*
|
1989-09-27 |
1991-07-16 |
Warner-Lambert Company |
Oral pharmaceutical composition for acid sensitive proteinaceous agents
|
US5643602A
(en)
*
|
1989-11-22 |
1997-07-01 |
Astra Aktiebolag |
Oral composition for the treatment of inflammatory bowel disease
|
SE8903914D0
(sv)
|
1989-11-22 |
1989-11-22 |
Draco Ab |
Oral composition for the treatment of inflammatory bowel diseases
|
JPH05507948A
(ja)
*
|
1990-04-18 |
1993-11-11 |
ユニバーシティ オブ ユタ リサーチ ファウンデーション |
アゾ結合を含み、pH依存性膨潤を示す、架橋したヒドロゲルに基づいた、結腸を標的にした経口薬の投薬形態
|
GB2253346A
(en)
*
|
1991-02-22 |
1992-09-09 |
John Rhodes |
Delayed release oral dosage forms for treatment of intestinal disorders
|
NL9002336A
(nl)
*
|
1990-10-24 |
1992-05-18 |
Leuven K U Res & Dev |
Bekledings- of matrixmateriaal voor geneesmiddelen.
|
US5316772A
(en)
*
|
1990-12-19 |
1994-05-31 |
Solvay & Cie, S.A. (Societe Anonyme) |
Bilayered oral pharmaceutical composition with pH dependent release
|
AU1587392A
(en)
*
|
1991-03-15 |
1992-10-21 |
Norwich Eaton Pharmaceuticals, Inc. |
The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
|
CA2148465C
(en)
*
|
1992-11-06 |
1999-11-02 |
Minenobu Okayama |
Oral pharmaceutical preparation releasable in the lower digestive tract
|
US5843479A
(en)
*
|
1993-02-26 |
1998-12-01 |
The Procter & Gamble Company |
Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
|
US5651983A
(en)
*
|
1993-02-26 |
1997-07-29 |
The Procter & Gamble Company |
Bisacodyl dosage form for colonic delivery
|
US5914132A
(en)
*
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
ES2149250T3
(es)
*
|
1993-04-23 |
2000-11-01 |
Novartis Ag |
Dispositivo para la administracion de medicamentos con liberacion controlada.
|
DK66493D0
(da)
*
|
1993-06-08 |
1993-06-08 |
Ferring A S |
Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
|
US6204243B1
(en)
|
1993-09-01 |
2001-03-20 |
Novatis Ag |
Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
|
US5500227A
(en)
*
|
1993-11-23 |
1996-03-19 |
Euro-Celtique, S.A. |
Immediate release tablet cores of insoluble drugs having sustained-release coating
|
US6210714B1
(en)
|
1993-11-23 |
2001-04-03 |
Euro-Celtique S.A. |
Immediate release tablet cores of acetaminophen having sustained-release coating
|
SE9401738D0
(sv)
*
|
1994-05-19 |
1994-05-19 |
Ewos Ab |
Bioactive feed
|
GB9412394D0
(en)
*
|
1994-06-21 |
1994-08-10 |
Danbiosyst Uk |
Colonic drug delivery composition
|
GB2303550B
(en)
*
|
1994-06-21 |
1998-07-08 |
Danbiosyst Uk |
Colonic drug delivery system
|
US5637319A
(en)
*
|
1995-03-01 |
1997-06-10 |
Takada; Kanji |
Controlled-release preparations
|
US6166024A
(en)
*
|
1995-03-30 |
2000-12-26 |
Mayo Foundation For Medical Education And Research |
Use of topical azathioprine and thioguanine to treat colorectal adenomas
|
US20040018236A1
(en)
*
|
1995-05-08 |
2004-01-29 |
Robert Gurny |
Nanoparticles for oral administration of pharmaceutical agents of low solubility
|
US5686106A
(en)
*
|
1995-05-17 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form for colonic delivery
|
US6156340A
(en)
*
|
1996-03-29 |
2000-12-05 |
Duquesne University Of The Holy Ghost |
Orally administrable time release drug containing products
|
AU2521797A
(en)
*
|
1996-04-12 |
1997-11-07 |
Japan Atomic Energy Research Institute |
Ph-sensitive polymers
|
GB9620709D0
(en)
*
|
1996-10-04 |
1996-11-20 |
Danbiosyst Uk |
Colonic delivery of weak acid drugs
|
DE19732903A1
(de)
|
1997-07-30 |
1999-02-04 |
Falk Pharma Gmbh |
Pellet-Formulierung zur Behandlung des Intestinaltraktes
|
EP1101490B1
(de)
|
1998-07-28 |
2005-04-13 |
Tanabe Seiyaku Co., Ltd. |
Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
|
AU5654699A
(en)
*
|
1998-09-21 |
2000-04-10 |
Amato Pharmaceutical Products, Ltd. |
Oral drug delivery system for enhancing the bioavailability of activated glycyrrhetin
|
US6322819B1
(en)
|
1998-10-21 |
2001-11-27 |
Shire Laboratories, Inc. |
Oral pulsed dose drug delivery system
|
IT1303753B1
(it)
*
|
1998-11-13 |
2001-02-23 |
Ct Lab Farm Srl |
Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
|
NZ513037A
(en)
|
1999-01-29 |
2003-05-30 |
Disphar Internat B |
Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
|
JP2000247911A
(ja)
|
1999-02-26 |
2000-09-12 |
Hisamitsu Pharmaceut Co Inc |
大腸用吸収促進剤
|
CN1173695C
(zh)
|
1999-06-14 |
2004-11-03 |
科斯默股份公司 |
控制释放与掩蔽味道的口服药物组合物
|
US8895064B2
(en)
|
1999-06-14 |
2014-11-25 |
Cosmo Technologies Limited |
Controlled release and taste masking oral pharmaceutical composition
|
IL130602A0
(en)
|
1999-06-22 |
2000-06-01 |
Dexcel Ltd |
Stable benzimidazole formulation
|
US6620834B1
(en)
|
1999-07-02 |
2003-09-16 |
Hisamitsu Pharmaceutical Co., Inc. |
Medicinal compositions for treating colorectal cancer
|
US20030114349A1
(en)
*
|
2000-04-27 |
2003-06-19 |
The Procter & Gamble Company |
Coating composition for solid bodies
|
IL153514A0
(en)
|
2000-06-21 |
2003-07-06 |
Cubist Pharm Inc |
Compositions and methods to improve the oral absorption of antimicrobial agents
|
TWI249519B
(en)
|
2000-08-29 |
2006-02-21 |
Nobex Corp |
Immunoregulatory compounds and derivatives and methods of treating diseases therewith
|
CA2359812C
(en)
*
|
2000-11-20 |
2004-02-10 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
|
US20070059368A1
(en)
*
|
2005-05-31 |
2007-03-15 |
Cherukuri S R |
Modified release formulations of anti-irritability drugs
|
US8048924B2
(en)
|
2001-08-29 |
2011-11-01 |
Biocon Limited |
Methods and compositions employing 4-aminophenylacetic acid compounds
|
US8282955B2
(en)
*
|
2001-10-15 |
2012-10-09 |
Ferring B.V. |
Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
|
US20070042143A1
(en)
*
|
2003-04-23 |
2007-02-22 |
Ferring B.V. |
Sachet for a pharmaceutical composition
|
CN1972698B
(zh)
|
2003-09-01 |
2010-06-02 |
有限会社爱泽世 |
β-羟基短-中链脂肪酸聚合物
|
US7825106B2
(en)
|
2003-09-03 |
2010-11-02 |
Agi Therapeutics Ltd. |
Modified release formulations and methods of treating inflammatory bowel disease
|
US7737133B2
(en)
*
|
2003-09-03 |
2010-06-15 |
Agi Therapeutics Ltd. |
Formulations and methods of treating inflammatory bowel disease
|
AU2004314731B2
(en)
*
|
2004-01-20 |
2011-07-07 |
The Board Of Regents Of The University Of Oklahoma |
Compositions and methods of treatment for inflammatory diseases
|
EP2361620B1
(de)
|
2004-02-06 |
2016-04-06 |
PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST |
Verwendung von aminosalicylaten beim reizdarmsyndrom mit durchfall als vorherrschendem symptom
|
KR20130028807A
(ko)
*
|
2004-05-28 |
2013-03-19 |
샐릭스 파마슈티컬스 인코포레이티드 |
방사선 유발성 장염의 예방, 치료 및 개선 방법
|
CA2572223C
(en)
|
2004-06-25 |
2014-08-12 |
The Johns Hopkins University |
Angiogenesis inhibitors
|
PL1773767T3
(pl)
|
2004-07-07 |
2016-07-29 |
Biocon Ltd |
Synteza azowo związanych związków immunoregulacyjnych
|
ATE424189T1
(de)
*
|
2004-09-01 |
2009-03-15 |
Procter & Gamble |
Zusammensetzungen mit 5-amino-2- hydroxybenzoesäure und einem reduzierendem zucker
|
US9149439B2
(en)
*
|
2005-03-21 |
2015-10-06 |
Sandoz Ag |
Multi-particulate, modified-release composition
|
US20090017110A1
(en)
*
|
2005-05-31 |
2009-01-15 |
Capricorn Pharma Inc. |
Modified release formulations of anti-irritability drugs
|
US7452872B2
(en)
|
2005-08-24 |
2008-11-18 |
Salix Pharmaceuticals, Inc. |
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
|
US8921344B2
(en)
*
|
2006-11-03 |
2014-12-30 |
Salix Pharmaceuticals, Inc. |
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
|
CN102670626A
(zh)
*
|
2005-08-24 |
2012-09-19 |
萨利克斯药品公司 |
巴柳氮制剂及其生产和应用
|
US7964215B1
(en)
|
2006-01-24 |
2011-06-21 |
Emet Pharmaceuticals, LLC |
Delayed release dosage form
|
GB0607534D0
(en)
*
|
2006-04-13 |
2006-05-24 |
Univ London Pharmacy |
Colonic drug delivery formulation
|
US20110144188A1
(en)
*
|
2006-06-06 |
2011-06-16 |
Antibe Therapeutics Inc. |
Salts of trimebutine and n-desmethyl trimebutine
|
BRPI0622008A2
(pt)
*
|
2006-09-13 |
2011-12-20 |
Procter & Gamble |
métodos de tratamento para colite ulcerativa
|
AU2006348138A1
(en)
*
|
2006-09-13 |
2008-03-20 |
Warner Chilcott Company, Llc |
Methods of treatment for ulcerative colitis using aminosalicylate
|
WO2008085484A2
(en)
*
|
2006-12-28 |
2008-07-17 |
Jacobus Pharmaceutical Company, Inc. |
Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
|
US20090028944A1
(en)
*
|
2007-07-16 |
2009-01-29 |
Balaji Sathurappan |
Pharmaceutical compositions comprising mesalamine
|
US20090036414A1
(en)
*
|
2007-08-02 |
2009-02-05 |
Mutual Pharmaceutical Company, Inc. |
Mesalamine Formulations
|
US20090162434A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Disphar International Bv |
Mesalazine tablet
|
US20090169622A1
(en)
*
|
2007-12-27 |
2009-07-02 |
Roxane Laboratories, Inc. |
Delayed-release oral pharmaceutical composition for treatment of colonic disorders
|
NZ592049A
(en)
*
|
2008-10-03 |
2012-11-30 |
Falk Pharma Gmbh |
Compositions and methods for the treatment of bowel diseases with granulated mesalamine
|
ES2641471T3
(es)
|
2008-10-06 |
2017-11-10 |
The Johns Hopkins University |
Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
|
US9463163B2
(en)
|
2009-10-16 |
2016-10-11 |
Sun Pharmaceutical Industries Limited |
Delayed release pharmaceutical composition of mesalamine
|
US10154964B2
(en)
|
2011-09-07 |
2018-12-18 |
Cosmo Technologies Limited |
Controlled release and taste masking oral pharmaceutical composition
|
RU2014141201A
(ru)
|
2012-03-29 |
2016-05-20 |
ТЕРАБАЙОМ, ЭлЭлСи |
Композиции для желудочно-кишечной сайт-специфической пероральной вакцинации, проявляющие активность в подвздошной кишке и аппендиксе
|
US20140066837A1
(en)
|
2012-07-26 |
2014-03-06 |
Ronald L. Moy |
Skin care compositions and methods
|
US20140141075A1
(en)
|
2012-11-21 |
2014-05-22 |
Warner Chilcott Company, Llc |
5-aminosalicylic acid capsule formulation
|
RU2015140610A
(ru)
|
2013-03-14 |
2017-04-17 |
ТЕРАБАЙОМ, ЭлЭлСи |
Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
|
JP6294457B2
(ja)
|
2013-03-15 |
2018-03-14 |
ワーナー チルコット カンパニー, エルエルシーWarner Chilcott Company, Llc |
低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物
|
US9539265B2
(en)
|
2013-03-15 |
2017-01-10 |
Aihol Corporation |
Pharmaceutical formulation containing glycosaminoglycan
|
CN117815373A
(zh)
|
2013-04-07 |
2024-04-05 |
博德研究所 |
用于个性化瘤形成疫苗的组合物和方法
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
KR20230076867A
(ko)
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
CA3018328A1
(en)
|
2014-10-31 |
2016-04-30 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
WO2016100977A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Methods for profiling the t-cel- receptor repertoire
|
RU2733754C2
(ru)
|
2015-05-20 |
2020-10-06 |
Те Брод Инститьют Инк. |
Общие неоантигены
|
CA3133710C
(en)
|
2015-11-02 |
2023-10-24 |
Pura Scents, Inc. |
Scent dispensation
|
USD809116S1
(en)
|
2015-11-02 |
2018-01-30 |
Pura Scents |
Dispenser
|
USD816506S1
(en)
|
2015-11-02 |
2018-05-01 |
Pura Scents, Inc. |
Vial for a scent dispenser
|
EP3446119A1
(de)
|
2016-04-18 |
2019-02-27 |
The Broad Institute Inc. |
Verbesserte hla-epitopvorhersage
|
EP3257501A1
(de)
|
2016-06-14 |
2017-12-20 |
Tillotts Pharma AG |
Aus mehreren einzeleinheiten zusammengesetzte dosierungsform mit einem kern aus individuellen kerneinheiten, die mit mukoadhäsivem material bedeckt sind, sowie einer enterischen kernbeschichtung
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
US10098898B1
(en)
|
2017-12-04 |
2018-10-16 |
Handa Pharmaceuticals, Llc |
Release stable mesalamine dosage forms
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CN116249774A
(zh)
|
2020-05-26 |
2023-06-09 |
迪奥尼斯治疗公司 |
核酸人工微型蛋白质组文库
|
WO2023076733A1
(en)
|
2021-11-01 |
2023-05-04 |
Dana-Farber Cancer Institute, Inc. |
Biologically selected nucleic acid artificial mini-proteome libraries
|